AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own CVR Partners, you generally have to believe in the durability of its nitrogen fertilizer cash flows, its ability to run hard, and management’s discipline in handing excess cash back to unitholders. The latest quarter reinforces that story: Q2 2026 showed strong sales and earnings, very high 99% ammonia utilization, and another large cash distribution, all while the Coffeyville shift toward natural gas and the East Dubuque expansion aim to keep the plants flexible and incrementally larger over time. At the same time, the new Q3 guidance for materially lower ammonia utilization around 75% to 80% brings short term operational risk back into focus, especially with an East Dubuque turnaround pending. For now, the news looks more like a reminder of how cyclical volumes and plant downtime can be than a fundamental break in the thesis.
However, one key operational swing factor could matter more than recent strong results suggest. CVR Partners' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore another fair value estimate on CVR Partners - why the stock might be worth over 3x more than the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com